NY-ESTÉE-LAUDER
5.4.2024 15:26:35 CEST | Business Wire | Press release
TOM FORD announced today that Dexter King has been appointed Senior Vice President, Global General Manager, TOM FORD BEAUTY. King will step into this role effective April 1, 2024 and continue reporting to Guillaume Jesel, President and CEO, TOM FORD and Luxury Business Development, The Estée Lauder Companies. King will also join The Estée Lauder Companies (NYSE:EL) Extended Executive Leadership Team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240405576513/en/
Dexter King has been appointed Senior Vice President, Global General Manager, TOM FORD BEAUTY. (Photo: Business Wire)
King has been with TOM FORD BEAUTY for nine years, working in a number of key leadership roles including most recently as Senior Vice President (SVP), Global Marketing and Strategy, and prior to then as SVP, General Manager, International and Global Strategy. In close partnership with Jesel, under King’s leadership of strategy and International, the brand elevated key TOM FORD fragrances to the luxury tier, accelerated its channel strategy and achieved exceptional growth and share gains across key markets.
“Dexter’s multi-faceted leadership experience at TOM FORD BEAUTY has been instrumental in helping the brand achieve exceptional global growth,” said Jesel. “His deep understanding of luxury, the importance of aspirational local relevance, and his command of the strategic growth opportunities in the luxury sector make him well-suited to lead the continued global momentum of TOM FORD BEAUTY.”
In his new role, King will lead the TOM FORD BEAUTY team in all aspects of category, channel and geography strategic growth plans. He will focus on driving the brand’s luxury beauty positioning through world-class innovation across makeup, fragrance and skincare and continue to elevate the brand’s signature aspirational storytelling of modern luxury glamour and amplifying individual beauty.
Prior to TOM FORD BEAUTY, King worked in strategy and marketing roles, holding positions of increasing responsibility across companies including McKinsey & Company, Diageo, and Moët Hennessy. King holds a Master of Business Administration from The Fuqua School of Business at Duke University and a Bachelor of Arts in Economics from the University of Virginia.
About TOM FORD
TOM FORD IS A GLOBAL DESIGN HOUSE OFFERING EXCEPTIONAL LUXURY PRODUCTS ACROSS WOMEN’S AND MEN’S FASHION, ACCESSORIES, EYEWEAR AND BEAUTY. FOUNDED IN 2005 BY TOM FORD, TODAY THE BRAND HAS A PRESENCE IN MORE THAN 100 MARKETS GLOBALLY, AND IS WIDELY RECOGNIZED AS THE ARCHITECT OF LUXURY GLAMOUR. IN 2023, THE ESTÉE LAUDER COMPANIES BECAME THE SOLE OWNER OF THE TOM FORD BRAND AND ALL ITS INTELLECTUAL PROPERTY. IN APRIL 2023 PETER HAWKINGS WAS APPOINTED THE CREATIVE DIRECTOR OF TOM FORD.
About TOM FORD BEAUTY
TOM FORD IS A GLOBAL DESIGN HOUSE OFFERING EXCEPTIONAL LUXURY PRODUCTS ACROSS WOMEN’S AND MEN’S FASHION, ACCESSORIES, EYEWEAR AND BEAUTY. FOUNDED IN 2005 BY TOM FORD, TODAY THE BRAND HAS A PRESENCE IN MORE THAN 100 MARKETS GLOBALLY, AND IS WIDELY RECOGNIZED AS THE ARCHITECT OF LUXURY GLAMOUR. TOM FORD BEAUTY IS DESIGNED TO AMPLIFY INDIVIDUAL BEAUTY WITH A COLLECTION OF SUMPTUOUS COSMETICS, EXTRAORDINARY FRAGRANCES AND ADVANCED SKINCARE.
ELC-B
NYSE: EL
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240405576513/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom